Advertisement
Advertisement

NKTR

NKTR logo

Nektar Therapeutics

36.77
USD
Sponsored
+1.66
+4.71%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

37.08

+0.30
+0.83%

NKTR Earnings Reports

Positive Surprise Ratio

NKTR beat 32 of 40 last estimates.

80%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$10.39M
/
-$2.47
Implied change from Q3 25 (Revenue/ EPS)
-11.87%
/
+32.09%
Implied change from Q4 24 (Revenue/ EPS)
-64.38%
/
+2.92%

Nektar Therapeutics earnings per share and revenue

On Nov 06, 2025, NKTR reported earnings of -1.87 USD per share (EPS) for Q3 25, beating the estimate of -2.73 USD, resulting in a 31.71% surprise. Revenue reached 11.79 million, compared to an expected 10.25 million, with a 15.03% difference. The market reacted with a +1.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -2.47 USD, with revenue projected to reach 10.39 million USD, implying an increase of 32.09% EPS, and decrease of -11.87% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Nektar Therapeutics reported EPS of -$1.87, beating estimates by 31.71%, and revenue of $11.79M, 15.03% above expectations.
The stock price moved up 1.54%, changed from $55.12 before the earnings release to $55.97 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 10 analysts, Nektar Therapeutics is expected to report EPS of -$2.47 and revenue of $10.39M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement